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Since 2007, in response to the growing epidemic of 
drug-resistant tuberculosis (DR-TB) in Khayelitsha, 
Médecins Sans Frontières (MSF), the City of Cape 
Town and the Provincial Government of the Western 
Cape are carrying out a pilot project to provide 
treatment to DR-TB patients at the primary care 
level. Khayelitsha is a township with one of the 
highest burdens of HIV infection and tuberculosis 
across South Africa and globally.
The Khayelitsha DR-TB Programme demonstrates 
how a patient-centred, decentralised model of 
care can increase case detection and improve 
treatment outcomes; thereby reducing further 
DR-TB transmission.  The model is based on 
the understanding that the majority of DR-TB is 
transmitted by patients who are not on treatment. 
Consequently, the major objectives are to increase 
case detection, decrease time to diagnosis and 
Executive Summary
TB programme staff
Standard recording and reporting
Drug supply and management
Laboratory support
HIV/TB integrated services
Treatment supporters
E
x
i
s
t
i
n
g
 
T
B
 
p
r
o
g
r
a
m
m
e
Staff training, clinical support
DR-TB counselling, social assistance and 
programme supervision
DR-TB recording (evaluation)
TB infection control
Local inpatient service
Specialist outreach services – paediatrics, 
audiometry screening
D
R
-
T
B
 
a
d
d
i
t
i
o
n
a
l
 
i
n
p
u
t
s
treatment initiation, optimise treatment outcomes 
and optimise infection control. The programme 
has been gradually implemented over three years, 
based on increasing experience, monitoring of 
outcomes and continuous re-evaluation. 
In order to integrate DR-TB care and treatment into 
the existing TB programme at primary care level, 
a range of additional supports have been provided 
(see diagram). Although the model of care in 
Khayelitsha has been developed specifically for this 
setting, the majority of these interventions are likely 
to be feasible and sustainable across a range of 
different settings with minimal adaptation. 
While a number of challenges remain, the 
successes of the programme may guide efforts to 
increase access to treatment and improve outcomes 
for patients elsewhere. 2
Key successes include:
Improved case detection;   the number of cases diagnosed in Khayelitsha has increased from 118 in 2006 to 231 
in 2009. This is the result of intensive training of health care workers promoting increased awareness of DR-TB and 
enabling more effective management of DR-TB patients at primary care level
Improved initiation of treatment;   more than 80% of patients diagnosed in 2009 and 2010 were started on 
treatment. The median time to treatment initiation has decreased from 71 days in 2007 to 33 days in 2010
Improved treatment regimens;   the treatment regimen in Khayelitsha has been strengthened by the inclusion of 
moxifloxacin (instead of ofloxacin) and terizidone for all patients. Ongoing treatment is guided by the availability 
of second-line drug susceptibility results in close to 90% of patients, increased from only 35% in 2007.  Twenty 
percent of patients found to have initially undetected second-line resistance in 2009 and 2010 were able to receive 
an effective regimen from the outset, preventing the development of further resistance while awaiting second-line 
drug susceptibility results
Ambulatory treatment;   in 2010, 72% of patients were able to start treatment at their local clinic, 15% at the 
community-based sub-acute facility in Khayelitsha and only 13% were admitted to the centralised DR-TB hospital; 
thereby reducing the demand for scarce hospital beds and allowing clinically stable patients to remain in their 
communities with support from their families
TB infection control;   measures to reduce the risk of nosocomial TB transmission have been implemented in all 
primary health care facilities and the sub-acute inpatient facility in Khayelitsha. In addition, activities to increase 
community awareness and provide information on infection control are provided to the general community at taxi 
ranks, churches and shopping malls 
Improving patient support;   patients are receiving initial one-on-one counselling, ongoing adherence support at 
weekly support groups, as well as dedicated home visits to support and educate the family, assess infection control 
measures and trace contacts
Improved survival;   Among patients diagnosed with DR-TB in 2008, 62% were alive at 18 months after diagnosis. 
Given that 76% of all DR-TB patients are HIV infected, this represents a significant improvement from that reported 
elsewhere
Many of the challenges faced in Khayelitsha are 
common to programmes aiming to scale up DR-TB 
treatment globally, especially the lack of access 
to rapid diagnosis of drug resistance for all TB 
patients, long and difficult treatment regimens that 
lead to high rates of default from treatment and a 
lack of new drugs to improve treatment outcomes 
and reduce the risk of treatment failure. 
In Khayelitsha, and indeed in many other parts of 
South Africa, increased access to newer and more 
rapid diagnostic tools will enable case detection to 
be improved dramatically. Currently, it is estimated 
that approximately only half of DR-TB cases in 
Khayelitsha are diagnosed. Although this is a 
dramatic success when compared to the barely 3% 
that have access to appropriate treatment globally, 
this will need to be increased substantially if we are 
to ultimately control the DR-TB epidemic.
Simple measures such as the introduction of DR-
TB registers in all primary health care facilities will 
enable a more accurate assessment of the DR-TB 
burden in the community, and therefore more 
accurate national reporting. 
In addition, new approaches to reducing the 
proportion of patients who fail treatment through 
earlier identification and access to a wider range 
of drugs are needed. Providing care for patients 
in whom treatment has failed and who remain 
infectious will require balancing the individual’s 
rights to care and treatment with protection of the 
community.
The successes demonstrated in the Khayelitsha DR-
TB programme show that diagnosing and treating 
drug resistant TB through the primary health care 
system is essential if the thousands of prevalent 
cases throughout South Africa are to be offered 
treatment and a chance of cure. Decentralisation 
of treatment will, however, require the commitment 
of resources to the primary care level, away from 
expensive hospital-based programmes. Given 
the high cost of treating just one patient for drug 
resistant TB, prevention through treatment of 
existing cases should be of the highest priority. Introduction
Khayelitsha is the largest township in South Africa’s 
Western Cape Province. It lies 40 kilometres from 
Cape Town and is home to at least 500,000 
people, over half of whom are unemployed. 
Khayelitsha has one of the highest burdens of HIV 
infection and tuberculosis (TB) both in the country 
and globally. In 2009, antenatal HIV prevalence 
was 30% and the case notification rate for TB was 
at least 1,500 per 100,000 people per year – 
among the highest estimated TB incidence rates in 
the world [1]. 
Médecins Sans Frontières (MSF) started working in 
Khayelitsha in 1999 supporting a pilot programme 
to prevent mother-to-child-transmission of HIV. 
In 2001, the first patient in Khayelitsha received 
antiretroviral therapy (ART) through a pilot 
programme supported by MSF that has been 
subsequently integrated into the Western Cape 
Province ART programme. By the end of 2010, 
more than 15,000 people had been successfully 
started on life-saving ART in Khayelitsha. Successes 
have also been seen the in the treatment of TB; in 
2009, 81% of new sputum smear positive cases 
and 65% of retreatment smear positive patients 
were successfully treated. The proportion of new 
smear positive patients not completing treatment 
was 7.7%, and 17% for retreatment smear positive 
patients [1]. 
Despite these successes, Khayelitsha has a 
growing epidemic of drug-resistant TB (DR-TB), 
an epidemic that threatens both the success of the 
National Tuberculosis Programme and the gains 
made through expanding access to antiretroviral 
treatment for HIV. Given this emerging threat, it 
is necessary to rapidly diagnose and effectively 
treat as many DR-TB cases as possible in order to 
prevent further progression of the epidemic. In light 
of national policy to centralise treatment through 
hospitalisation of all DR-TB patients, Khayelitsha 
was one of the early pilot sites for decentralised 
care and expanded access to effective treatment 
for DR-TB in South Africa. This report describes 
the DR-TB model of care as it has developed in 
Khayelitsha, along with the key achievements to 
date and the challenges that remain.
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The Burden of DR-TB 
in Khayelitsha
South Africa has one of the highest burdens of 
DR-TB globally, with close to 10,000 patients 
diagnosed with multi-drug resistant (MDR) TB in 
2009 [2]. In Khayelitsha, there is a particularly 
high level of DR-TB. A survey carried out at two 
sites in Khayelitsha conducted by MSF, the City 
of Cape Town and the National Health Laboratory 
Service (NHLS) in 2008/09 found that 5.2% of 
new TB cases and 11.1% of previously treated TB 
cases were due to rifampicin-resistant strains [3]. If 
applied to the actual number of TB cases diagnosed 
in 2008, these figures indicate that if all TB cases 
in Khayelitsha were to be screened for DR-TB, close 
to 400 would be diagnosed each year, leading to 
an estimated incidence of close to 80 per 100,000/
year (Table 1). More than half of these cases 
occur among TB patients who have not previously 
received TB treatment, indicating that most DR-TB 
in Khayelitsha is transmitted, rather than acquired 
through inadequate TB treatment. This ongoing 
community transmission of DR-TB, especially 
among the vulnerable HIV infected population, is 
highly likely to be driving this epidemic. 
Earlier diagnosis and treatment will both reduce 
transmission and improve treatment outcomes. The 
Khayelitsha pilot project is based on the premise 
that, in a high TB/HIV prevalence setting, the 
burden of DR-TB may best be reduced by: 
a community-based approach 
improved case detection strategies  
increased access to quality-assured  
medications in robust combinations 
New TB cases Previously treated TB cases
Number of culture positive TB cases in survey 269 261
Susceptible 236 211
Rifampicin mono-resistance 5 (1.9%) 9 (3.4%)
Isoniazid mono-resistance 19 (7.1%) 21 (8.0%)
MDR-TB 9 (3.3%) 20 (7.7%)
Any rifampicin resistance 14 (5.2%) 29 (11.1%)
Any isoniazid resistance 28 (10.4%) 41 (15.7%)
Number of TB cases diagnosed in Khayelitsha in 
2008
4279 1542
Estimated % of rifampicin-resistant TB (from survey) 5.2% 11.1%
Estimated number of rifampicin resistant TB cases if 
all screened for DR-TB
223 168
Total estimated rifampicin resistant TB cases in 2008 391
Table 1 Results of a drug resistance survey conducted in Khayelitsha in 2008/2009 [3].5
shortening the time to both diagnosis and  
treatment initiation 
prioritizing TB infection control in health  
facilities  
intensified patient support to ensure  
adherence. 
Of the estimated 391 cases of DR-TB in Khayelitsha 
in 2008, only 211 (54%) were diagnosed. In 
such a high DR-TB burden context as this, every 
TB patient should be tested for drug resistance to 
achieve the necessary coverage. However current 
guidelines only recommend testing for DR-TB in 
patients who were previously treated for TB or who 
are not responding to TB treatment.
'UXJUHVLVWDQWWXEHUFXORVLVGH¿QLWLRQV
In this report, DR-TB refers to patients who are infected with TB bacteria that are: 
Resistant to the two most important first-line anti-tuberculosis drugs (rifampicin and isoniazid),  
therefore defined as ‘multidrug resistant’ or MDR
Resistant to rifampicin alone, therefore defined as ‘rifampicin mono-resistant’ 
Resistant to rifampicin, isoniazid and two of the most important classes of second-line anti- 
tuberculosis drugs, namely a fluoroquinolone (such as ofloxacin) and an injectable drug (either 
amikacin, kanamycin or capreomycin), therefore defined as ‘extensively drug-resistant’ or XDR
Resistant to isoniazid and rifampicin (i.e. MDR-TB) as well as either one of the fluoroquinolone  
drugs OR any of the three injectable second-line anti-TB drugs (amikacin, kanamycin or 
capreomycin), therefore defined as pre-XDR
Given that all DR-TB patients require second-line anti-tuberculosis treatment and that patients can 
be infected with strains of TB bacteria having a wide range of possible combinations of resistance to 
different drugs, we use the term drug resistant TB (DR-TB) throughout this report6 2
The Khayelitsha Model 
of Care for DR-TB
Principles of the Khayelitsha Model
The Khayelitsha DR-TB programme has been 
implemented based on principles of respect for 
individual patient rights as well as public health 
protection, integration into existing TB services, the 
need for intensified TB infection control measures 
at all levels, an understanding that the majority of 
community transmission occurs prior to initiation 
of treatment and that ambulatory treatment can be 
implemented without posing an increased risk for 
community transmission (see box). 
The model of care now being implemented in 
Khayelitsha has developed in a progressive 
manner since late 2007. Not all components 
were implemented initially; rather, changes and 
new initiatives were introduced as the programme 
developed and lessons were learned.
The aim of this report is to offer the experience 
in Khayelitsha as an example of how this model 
of care may be adapted and developed within 
the context of a particular setting, rather than as 
a ‘prescription’ of what should be done in any 
situation. Other settings will be different, both in 
terms of existing resources and further requirements 
needed to provide quality care to patients with 
DR-TB. The main focus should be on the actual 
services that are needed to provide decentralised 
patient care. Many of the activities may be carried 
out through existing support structures in primary 
health care clinics and therefore other settings may 
not require all of the additional resources described 
in this model. There may already be the capacity 
to expand existing activities to meet the objectives 
described, e.g. DR-TB data monitoring by existing 
TB data managers, use of a sub-acute step-down 
facility or hospital isolation ward for admission of 
patients when necessary or training of lay clinic 
staff to perform audiometry screening. 
BASIC PRINCIPLES OF 
IMPLEMENTATION:
Use of a patient-centred approach that places  
the patient at the centre of their treatment and 
respects human rights, paired with constant 
consideration for public health protection
Integration of DR-TB diagnosis and treatment  
into the routine TB programme and primary 
health care infrastructure
An understanding that the majority of DR-TB transmission occurs before patients are diagnosed and started on appropriate  
treatment. 
Acute awareness of the need for airborne infection control at all levels of health facilities, as well as at patients’ homes and  
within the community in general
With appropriate support, ambulatory treatment can be implemented without increased risk for community transmission  
The realisation that in high HIV/TB burden, low resource settings, centralised DR-TB programmes (i.e. mandatory hospital  
admission) have failed to contain the rise of DR-TB
A willingness to learn from the experience of TB programmes and ARV programmes, where decentralisation of nurse-based,  
integrated care and standardised protocols have resulted in increased access to care, high levels of adherence to treatment, 
and shorter delays between diagnosis and treatment initiation7
Initial Evaluation of the Setting
Implementation of the programme began in 
late 2007 with a review of the status of DR-TB 
diagnosis and treatment at that time. The key 
findings of this review included: long waiting times 
for hospital admission in order to initiate DR-TB 
treatment, high numbers of patients failing to be 
initiated on treatment or subsequently defaulting 
from treatment and inconsistent DR-TB screening or 
contact tracing. 
Health care workers at primary care level had 
limited knowledge and understanding of DR-TB, 
leading to fear of infection and negative attitudes 
toward patients. Once patients were diagnosed with 
DR-TB based on a laboratory result, a referral was 
simply sent to the specialist TB hospital without 
proper counselling or follow-up of the patient to 
ensure that they had commenced on or completed 
treatment. Poor understanding of TB and DR-TB 
transmission led to inconsistent implementation of 
airborne infection control measures in Khayelitsha 
clinics.
Monitoring and evaluation of DR-TB was also 
initially sub-optimal. There was a lack of data 
at primary care level regarding the numbers of 
patients diagnosed and their outcomes. Many 
diagnosed patients were never admitted to the 
specialist hospital for treatment, and therefore 
were never recorded as being diagnosed with DR-
TB. This situation resulted in a significant under-
estimate of the DR-TB burden. 
Phased Implementation 
One of the first steps to improve the situation was 
to introduce DR-TB registers into each clinic. The 
maintenance of this monitoring and reporting 
system is one of the cornerstones of the Khayelitsha 
programme, as it is used to assess progress towards 
the programme objectives. 
Another essential component of the programme 
was to provide extensive DR-TB training for health 
care workers in the clinics. Ongoing training and 
support of clinic staff and other stakeholders (e.g. 
other NGOs and community organisations) has 
enabled the gradual development and integration 
of the treatment process for DR-TB patients to 
be implemented at the primary care level. Figure 
1 details the components of this process, from 
increased case detection through to provision of 
additional patient support services, which have 
been introduced gradually over the past three years. 
Additional services in Khayelitsha: 
Clinical patient review meetings 
Audiometry screening 
Lizo Nobanda sub-acute inpatient  
facility
Paediatric outreach clinic 
Infection Control support for facilities 
Khayelitsha primary care clinic:
DST result received in clinic 
Medical Officer assessment and decision  
– clinic-based treatment vs hospital 
admission (direct referral)
Start DR-TB treatment (if clinic- 
based) using a six-drug strengthened 
standardized regimen:  kanamycin, 
moxifloxacin, terizidone, ethionamide, 
ethambutol, pyrazinamide
First counseling session at time of  
treatment start in clinic
Second counseling and infection  
control session in home (allowing for 
identification of ALL contacts)
Contact screening 
Receive second-line DST,  adjust treatment 
accordingly, ongoing monitoring:
Clinical patient review meetings 
Early identification and management of  
any side effects
Psychosocial and financial support  
(access to government and community 
support services)
Early defaulter tracing 
Re-screen contacts 
Figure 1: The diagnostic and treatment process 
in Khayelitsha.8
patients who do not smear or culture convert  
after 2 months of treatment or who re-convert 
after 5 months of TB treatment. 
HIV positive patients are at higher risk of developing 
any form of TB compared to HIV negative patients, 
and ideally all HIV-infected patients should be 
screened for DR-TB. However the high burden of 
HIV in Khayelitsha means that this would place 
massive demands on the current laboratory service 
if the current screening method of TB culture and 
drug susceptibility testing were to be used for such 
a large number of samples.
In 2009, only 29% of DR-TB cases diagnosed in 
Khayelitsha were new cases. However, based on 
the 2008/09 survey, more than half of all DR-TB 
cases in Khayelitsha should be in this category. It 
is likely that we are missing a large proportion of 
new DR-TB cases using the current case detection 
strategy. These data highlight the need to screen all 
TB cases for TB drug resistance, in order to allow 
for early diagnosis and treatment, and prevention 
of further spread of DR-TB. This requires improved 
access to more rapid diagnostic techniques, which 
would allow a larger number of samples to be 
screened. 
Increasing Diagnosis of DR-TB
As of December 2010, 989 individual patients with 
DR-TB had been diagnosed in Khayelitsha (Figure 
2). Since there is often a significant delay from 
the time patients give a sputum sample to receipt 
of the diagnostic sputum result in the clinic, total 
numbers for 2010 are expected to increase. In 
2009, 231 patients were diagnosed with DR-TB, 
giving a case notification rate of 45 per 100,000 
people per year (using an estimated population of 
500,000 in Khayelitsha). This number represents 
an estimated case detection rate of 54% when 
compared to the DR-TB prevalence as estimated by 
the survey done in 2008/09 [3]. Although this is a 
noteworthy achievement of the programme so far, 
further improvement to increase detection of DR-TB 
in Khayelitsha is still necessary and possible.
Education and training of clinic staff was necessary 
to raise awareness of the case detection strategy to 
increase diagnosis of DR-TB, by requesting sputum 
culture and drug susceptibility testing (DST) for 
TB patients at risk of DR-TB. Under current South 
African policy, only certain groups of patients are 
screened for drug resistance. These groups include: 
TB patients who have received TB treatment  
previously
close contacts of confirmed DR-TB patients 
high risk groups (health care workers, miners,  
prisoners)
patients who have a poor clinical response to  
TB treatment
Figure 2: Number of DR-TB cases diagnosed in Khayelitsha by year (2003 to December 2010)
*case detection to December, 2010
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 RAPID DIAGNOSTICS – CEPHEID XPERT MTB/RIF
During 2010 and continuing into 2011, a new rapid molecular test for TB and drug resistance 
(CEPHEID Xpert MTB/RIF, also known as ‘GeneXpert’) has been undergoing testing in Khayelitsha. 
This is being carried out as part of a multi-centric trial in collaboration with the University of Cape 
Town (UCT), the Foundation for Innovative New Diagnostics (FIND), the National Health Laboratory 
Service (NHLS), and the Provincial Administration of the Western Cape (PAWC) and City of Cape 
Town Departments of Health [4]. Initial results from the study conducted in one Khayelitsha clinic 
are promising, and for the first time allow for the potential to rapidly screen all TB suspects for DR-
TB in a high burden setting such as Khayelitsha. Efforts are currently underway to allow much wider 
access to this technology. If the Xpert MTB/RIF diagnostic could be used to test all TB suspects in 
Khayelitsha for DR-TB, we would expect to see dramatically increased case detection initially, followed 
by reductions over time as community transmission is reduced. 10
Improved case detection has also been 
demonstrated by the increasing proportions of 
DR-TB patients who are HIV infected (Figure 3). 
Among the 200 people diagnosed with DR-TB to 
date in 2010, the HIV status is known for 187 
(94%), of which 142 (77%) were found to be 
co-infected. This figure is now similar to that 
for drug-susceptible TB, whereas previously the 
percentage of HIV-infected DR-TB cases was lower. 
This suggests that HIV infected people most likely 
had died before a diagnosis of DR-TB could be 
made, as HIV-positive patients with DR-TB clinically 
deteriorate more quickly. This achievement also 
reflects improved HIV Counselling and Testing 
(HCT) coverage through greater integration of HIV 
and TB services in Khayelitsha. The increased 
proportion of co-infected patients suggests 
improved survival of HIV-infected DR-TB patients.
Initiating DR-TB Treatment at Pri-
mary Care Level
As DR-TB case detection increases, it is necessary 
to train and empower clinic administrative and 
health care staff to manage cases appropriately. 
When a laboratory result showing at least rifampicin 
resistance is received in any of the 10 primary 
care clinics in Khayelitsha, staff are required to 
register patients’ results in the DR-TB register, to 
rapidly recall the patients to clinic (using existing 
processes for follow-up of any other TB patients) 
and to ensure that they are referred to a doctor for 
clinical assessment. In some clinics, the doctor 
might only attend the clinic once or twice weekly, 
while in other larger clinics, a full time medical 
officer is available. At least one doctor per clinic in 
Khayelitsha has been trained in management of 
DR-TB patients through a number of dedicated DR-
TB training workshops and ongoing monthly clinical 
review meetings. 
Once the patient has been assessed and counselled 
by the doctor, a decision is made as to whether 
or not the patient requires hospital admission 
or is able to receive treatment through directly 
observed therapy (DOT) at the clinic on a daily 
basis. Experience has shown that the majority of 
patients diagnosed with DR-TB in Khayelitsha do 
not require hospitalisation based on their clinical 
condition – they are often well enough to attend 
the clinic daily to receive their second-line TB 
treatment on an ambulatory basis. This becomes 
particularly noticeable as clinic practices improve 
and patients are diagnosed with DR-TB earlier. This 
is not to say that hospitalisation is not necessary at 
all for DR-TB patients. As with drug sensitive TB, 
some DR-TB patients do become clinically unwell 
and may require hospitalisation at some point in 
their treatment. Therefore it remains necessary to 
maintain good communication links with tertiary 
services and to establish appropriate referral 
pathways between facilities. 
In 2010, only 14% of cases from Khayelitsha 
were admitted to the centralised specialist DR-TB 
hospital at the time of treatment initiation. A further 
15% of patients had their treatment started in the 
dedicated DR-TB sub-acute in-patient facility in 
Khayelitsha (see page 23), while 71% were able to 
start their treatment through their local primary care 
clinic (Figure 4). 
Figure 3: Percentage of diagnosed DR-TB cases who are co-infected with HIV
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Figure 4: site of DR-TB treatment initiation in Khayelitsha 2008 – 2010  (need to add 
earlier years to this)
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Managing XDR-TB at Primary Care 
Level?
Under current national policy, it is not possible 
to initiate treatment for extensively drug 
resistant (XDR) TB patients in their local clinics. 
Capreomycin is used to treat patients with 
demonstrated aminoglycoside (kanamycin 
or amikacin) resistance. While kanamycin is 
accessible as part of the standard regimen for 
MDR-TB in primary care clinics in Khayelitsha, 
capreomycin is currently only available for use 
in specialised DR-TB centres in South Africa. 
Therefore all patients requiring capreomycin 
have to be hospitalised in order to receive this 
medication. Due to the high demand for beds in the 
centralised TB hospital (which also serves many 
other surrounding sub-districts), an agreement was 
reached with them in early 2010 that patients in 
Khayelitsha may receive capreomycin if they are 
admitted in the sub-acute in-patient facility located 
in the community, (called Lizo Nobanda), provided 
the prescription is approved by a doctor from the 
TB hospital. Admissions to Lizo Nobanda for this 
reason are only intended to be for a short period 
in order to allow patients to commence treatment 
while they wait for a bed to become available at 
the specialist centre. While some patients with 
XDR-TB do require hospitalisation (as is the case 
for all TB), many are stable enough to attend their 
clinic daily to receive treatment; therefore a blanket 
policy to restrict access to capreomycin (and also 
PAS) in the community means that an unnecessary 
proportion of patients are admitted who could be 
managed in their local clinic. Indeed, given the 
delay in receiving second-line DST results, there are 
a number of patients who have already begun to 
receive clinic-based treatment for MDR-TB but who 
are then subsequently found to require capreomycin 
and have to be admitted to receive this treatment. 12
THE NEED FOR CAPREOMYCIN AT CLINIC LEVEL
Zyanda, a 35-year-old HIV-positive woman, presented at her local clinic in Khayelitsha with a persistent 
cough and night sweats and was started on regular TB treatment. Her sputum smear was negative, but 
her brother had been diagnosed with DR-TB the year before and had died in hospital, so the clinic staff 
sent her sputum for culture and DST. Apart from her symptoms, she was fairly well and was able to walk 
to the clinic daily to receive her treatment. She had no children and lived in a shack with her mother and 
her uncle, and was able to sleep in a separate room. After 3 weeks, the DST results on the positive MTB 
culture revealed that she had XDR-TB and required capreomycin as part of her treatment regimen because 
of demonstrated aminoglycoside resistance. 
Due to the policy of hospitalising all patients requiring capreomycin, a bed was requested at the specialist 
TB hospital, and in the meantime, Zyanda was admitted to the sub-acute inpatient facility in Khayelitsha to 
receive her DR-TB treatment, including the capreomycin injections. She remained in this community facility 
for a total of three months until a bed became available in the hospital. During that time she was monitored 
by the nurses according to the same protocol as that used in the primary care clinics in Khayelitsha. 
She saw a doctor once a week. She tolerated her treatment well and occasionally worked in the garden 
or helped the nurses to care for the other patients. After two months of treatment, her sputum cultures 
converted to negative, but according to the treatment protocol she was required to continue capreomycin for 
another four months. She was still only able to access capreomycin while admitted in the sub-acute facility 
or in hospital, despite remaining clinically stable and no longer posing an infection risk to others. 
When a bed became available in the TB hospital she was transferred there to complete the remaining three 
months of capreomycin injections before being discharged back to her clinic to receive oral medications 
for the remaining months of her treatment regimen. With the adequate clinical monitoring and support 
provided through the Khayelitsha decentralised DR-TB programme, Zyanda could have been managed well 
in her clinic, reducing the demand on beds in the TB hospital and allowing her to remain at home with her 
family. 13
Year Diagnosed
DR-TB Started on treatment (%) Died before starting 
treatment
2003/04 14 14 (100%) 0
2005 58 52 (90%) 0
2006 118 85 (72%) 10 (8%)
2007 157 106 (68%) 21 (13%)
2008 211 159 (75%) 24 (11%)
2009 231 195 (84%) 20 (9%)
2010 200* 164 (82%) 16 (8%)
Total 989 775 (78%) 91 (9%)
* Note that some of these patients may still start treatment.
Table 2: Number of diagnosed DR-TB patients who were started on second line TB treatment and the 
number who are known to have died before treatment could be started
Increasing the number of patients 
with DR-TB starting treatment
Improved case detection and early initiation of 
appropriate treatment, primarily through the 
provision of clinic-based ambulatory treatment 
are key factors in reducing overall mortality 
and preventing further cases due to ongoing 
transmission.  Since 2007, the numbers of 
patients initiating DR-TB treatment has increased 
dramatically in Khayelitsha (Table 2). These are 
patients that would otherwise remain untreated and 
therefore infectious, potentially spreading DR-TB in 
the community and in health facilities. 
Prior to 2007, the registration and reporting of 
DR-TB cases in Khayelitsha was inconsistent 
and incomplete; patients who were initiated on 
treatment were more likely to be registered at a 
centralised DR-TB centre called Brooklyn Chest 
Hospital (BCH), compared to those diagnosed but 
not started on DR-TB treatment (a survivor effect). 
Therefore, the percentage of recorded patients in 
whom treatment was initiated declined as reporting 
improved in 2006/07 and has now stabilised at 
around 80% in the last two years. 
Currently, the most common reason patients are 
not started on treatment is that they die between 
sputum sampling and the time that the result is 
reported from the laboratory, the patient located and 
treatment started. Pre-treatment mortality remains 
at approximately 10% of all diagnosed patients. 
This highlights the need to diagnose and start 
patients on DR-TB treatment as soon as possible. 
In 2007, it took a median of 71 days between 
sputum sampling and treatment initiation (Figure 
5). Although the time taken for TB to grow in 
culture is variable, the routine use of a molecular 
test, the Hain Line Probe Assay, for detecting 
resistance to rifampicin and isoniazid in the 
National Health Laboratory Service (NHLS) 
has reduced the delay in obtaining first line 
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Figure 5: Median number of days between sputum sampling and DR-TB treatment initiation14
RAPID DRUG RESISTANCE TESTING FOR ALL TB CASES 
Asanda, a 46-year-old HIV-positive man, was diagnosed clinically with sputum smear-negative 
pulmonary TB in October 2010 and was started on the standard first-line TB treatment in his local 
clinic. He was commenced on antiretroviral therapy (ART) two months after TB treatment had been 
established. A month later he became clinically unwell with increased cough, fever and a worsening 
chest X-ray. His sputum was again tested and had subsequently become smear-positive for TB. The 
sample was sent for further testing by culture and DST, and further antibiotics were added to his 
treatment to cover other non-TB infections. 
The sputum culture results came back a few weeks later demonstrating resistance to isoniazid and 
rifampicin; however by this stage Asanda had been admitted to hospital due to further deterioration 
of his condition. He was started on the standard treatment regimen for DR-TB, however he died a 
few days later. Had he been eligible for DR-TB screening initially, this man could have been correctly 
diagnosed from the beginning. More rapid diagnostics, available to all patients suspected of TB, 
would have meant Asanda could have started DR-TB treatment earlier and his death may have been 
prevented.       
susceptibility results on positive smears and 
cultures. In addition to the use of the Hain LPA, 
efforts to maximise the efficiency of existing 
processes have also helped to reduce the time from 
sputum sampling to DR-TB treatment initiation. 
These efforts include
prompt delivery of sputum samples to the  
laboratory 
timely reporting and delivery of results to the  
relevant clinics
rapid recall of patients to the clinic to see the  
doctor 
Although the time between sputum sampling and 
treatment initiation declined to 33 days in 2010 
it is still too long to avoid mortality in a significant 
number of cases. Among the 38 patients diagnosed 
with DR-TB in 2009 and 2010, who died before 
treatment could be initiated, the median time 
between sputum sampling and death was 25 days 
[5]. Expanded use of a rapid diagnostic test for DR-
TB such as the Xpert MTB/RIF (GeneXpert) offers 
an excellent opportunity to dramatically reduce 
early mortality.15
Strengthening the DR-TB Treatment 
Regimen 
Unlike antiretroviral drugs used in HIV treatment, 
there is no third-line treatment available for TB. 
Once the tuberculosis bacteria have developed 
resistance to first-line drugs, there is only a limited 
range of second-line drugs available to cure DR-TB. 
Many of these drugs have little evidence for efficacy 
and have a considerable risk of side effects. Once 
resistance has developed to second-line drugs, the 
chances of cure are severely limited [6]. As a result, 
when DR-TB is detected and treatment initiated, 
all efforts should be made to cure the patient using 
all available second-line drugs – there is essentially 
one chance of cure [7]. The use of a weakened 
regimen (i.e. with less than 4 active drugs) for any 
reason, either due to concerns over cost or attempts 
to reserve certain drugs, risks the creation of 
additional second-line resistance during treatment, 
thus severely limiting the patient’s chances of cure. 
In Cape Town, resistance to isoniazid and 
rifampicin is tested using a rapid molecular test 
(line probe assay) on positive sputum cultures 
[8]. To determine how many of these cases have 
Year MDR-TB* 2nd line DST results 
available  
(% of MDR-TB)
Ofloxacin 
resistance 
(% of 2nd line 
available)
Injectable resistance    
(% of 2nd line available)
XDR-TB        
(% of 2nd line 
available)
2007 126 43 (35%) 17 (40%) 17 (40%) 13 (30%)
2008 159 115 (74%) 20 (17%) 18 (16%) 11 (10%)
2009 169 145 (88%) 19 (13%) 17 (12%) 12 (8%)
2010† 161 123 (80%) 15 (12%) 23 (19%) 7 (6%)
Total 615 426 (69%) 71 (17%) 75 (18%) 36 (9%)
second-line drug resistance, further conventional, 
culture-based drug susceptibility testing (DST) is 
also conducted. Results for second-line resistance 
are often received some time after the patient has 
initiated treatment, and in some cases not at all. 
In Khayelitsha, the proportion of MDR-TB cases 
that have second-line DST results available from 
the time of diagnosis has increased dramatically 
from only 35% in 2007 to 88% in 2009 (Table 
3). This improvement was brought about initially 
by efforts to remind clinic staff to routinely request 
second-line DST on any positive cultures showing 
first line TB drug resistance, while more recently it 
has become standard procedure for the laboratory 
service to routinely carry out second-line testing on 
all samples resistant to isoniazid and rifampicin. 
Additional efforts to encourage staff to obtain a 
confirmatory sputum sample at treatment initiation, 
on which second-line DST can also be conducted, 
have also contributed to this increase. 
While the increased availability of second-line 
susceptibility results at clinic level is laudable, 
the data demonstrate alarmingly high levels of 
second-line resistance, prior to initiation of second-
line treatment. In 2009 and 2010, among the 
Table 3: Number of MDR-TB cases diagnosed in Khayelitsha, number with second-line DST results 
available, and number with additional resistance detected to ofloxacin and/or an injectable
*Laboratory confirmed MDR-TB cases (not all DR-TB cases)       
†Data for 2010 incomplete due to time taken for culture and DST 16
268 MDR-TB cases with available second-line 
DST, 13% were infected with strains having 
ofloxacin resistance, 15% with resistance to an 
aminoglycoside and/or capreomycin, and 7% were 
infected with XDR-TB strains. Overall, 20% of 
MDR-TB patients have resistance to either ofloxacin 
or an injectable or both. 
These figures suggest that a large proportion of 
DR-TB cases in Khayelitsha will not be effectively 
treated if a regimen that contains a limited number 
of second-line drugs to which the organism is 
susceptible is used in the initial treatment regimen. 
Instead, this has the potential to create further 
resistance (see box). 
In response to this risk, the Khayelitsha project 
has strengthened the initial drug regimen for DR-
TB; the regimen now includes moxifloxacin and 
terizidone for all patients starting DR-TB treatment. 
This will enable the 20% of patients with initially 
undetected second-line resistance to receive an 
effective regimen from the outset. Until recently, 
the standard regimen in South Africa included 
kanamycin, ofloxacin, ethambutol, ethionamide and 
pyrazinamide. In April 2010, the Western Cape 
Province provided terizidone for all DR-TB patients, 
replacing ethambutol in the standard regimen. 
Moxifloxacin has been used in Khayelitsha since 
2008; initially only for patients with demonstrated 
resistance to ofloxacin, but expanded to include all 
patients starting DR-TB treatment as of September 
2009. At that point, cycloserine was also added to 
the starting regimen, but was replaced by terizidone 
(a similar drug to cycloserine) in April 2010, when 
terizidone was provided for all DR-TB patients 
in the province. Therefore the initial treatment 
regimen for suspected and confirmed cases of DR-
TB in Khayelitsha currently consists of kanamycin, 
moxifloxacin, terizidone, ethionamide, ethambutol, 
and pyrazinamide
The necessity of a strengthened regimen is even 
further emphasised if widespread roll-out of the 
Xpert MTB/RIF (GeneXpert) test is to occur. This 
will mean that the gap between treatment initiation 
and receipt of second-line DST results will widen 
further.
ONE CHANCE OF CURE – THE NEED FOR A 
STRENGTHENED REGIMEN
In June 2009, Nosisi, a 47-year-old lady with TB symptoms, presented at a Khayelitsha clinic. 
She gave a sputum sample which was sent for culture and DST as she had been treated for TB 
two years previously. Three weeks later, laboratory results confirmed smear positive MDR-TB 
(resistance to both isoniazid and rifampicin using the line probe assay). Three days later, she 
was started on the standard DR-TB treatment regimen used at the time: kanamycin, ofloxacin, 
ethambutol, ethionamide and pyrazinamide. 
After she had been on treatment for 6 weeks, second-line DST results became available, showing 
resistance to ofloxacin but susceptibility to amikacin, ethambutol and ethionamide. Given that 
DST for both ethambutol and ethionamide is often unreliable [9, 10] and DST is not conducted 
for pyrazinamide, Nosisi may well have been receiving monotherapy with kanamycin for the first 6 
weeks of treatment. 
Although the treatment regimen was modified after the second-line DST results became available, 
and new drugs were added (including moxifloxacin and ethionamide), a culture taken at 5 months 
of treatment was positive and displayed resistance to amikacin. It is likely that this resistance 
developed during the first six weeks of treatment, while Nosisi was receiving an inadequate 
regimen.17
Patient Adherence Support
Second-line treatment for DR-TB is long and 
difficult. Patients receive painful injections for at 
least 6 months and several of the second-line 
drugs are associated with significant and potentially 
debilitating side effects. Patients are often required 
to attend clinics each day and are occasionally 
hospitalised to receive treatment, making it difficult 
to continue working or to support families. A 
diagnosis of MDR-TB or XDR-TB is also associated 
with stigma and is often perceived as a death 
sentence by patients. For these reasons, counselling 
and treatment literacy are essential components of 
the Khayelitsha programme. 
Once a patient has been diagnosed with DR-TB 
and a decision made on where treatment is to be 
initiated, the patient is then counselled by one of 
three counsellors dedicated for DR-TB patients. 
This requires an appropriate system of referral and 
good communication between the doctor or TB 
nurses and the counsellors. The first counselling 
session takes place in the clinic, preferably on the 
same day as the patient receives the diagnosis, 
and the counsellor explains what DR-TB is, how it 
is treated and what the patient will need to do to 
complete treatment and be cured. The counsellors 
use lay terms and culturally appropriate language, 
often repeating what has been explained to them 
by the doctor. Among the 409 patients starting DR-
TB treatment in 2009 and 2010 in Khayelitsha, 
301 (73%) were counselled by a dedicated DR-TB 
counsellor at the time of treatment initiation.
For ambulatory patients who receive treatment 
through the clinic, a home visit is conducted as 
soon as possible after the patient has received the 
initial counselling session and started treatment. 
One of the DR-TB counsellors along with one other 
person, either the social worker, nurse or peer 
educator, go together into the community to visit the 
patient in their usual place of residence. The aims 
of this visit are several-fold: 
re-emphasising some of the issues raised in  
the first counselling session and discussing 
any further questions
involving other family or household members  
in supporting the patient to take treatment
providing education and support to both  
the patient and the household members to 
enable them to minimise the risk of DR-TB 
transmission
to initiate screening for DR-TB among close  
household contacts, particularly children
Patients are also encouraged to attend weekly DR-
TB support groups, which are run by an adherence 
counsellor together with a peer educator. Support 
5DWLRQDOHIRU8VHRI0R[LÀR[DFLQ
Although all fluoroquinolones have activity against Mycobacterium tuberculosis, the newer generation 
fluoroquinolones, including moxifloxacin, appear to be particularly efficacious [11-13]. Currently, 
therapeutic options for treating MDR-TB are extremely limited and treatment outcomes are particularly 
poor when fluoroquinolone resistance has developed [14,15]. Moxifloxacin, a newer fluoroquinolone with 
greater anti-TB activity than ofloxacin, has considerable potential to improve the treatment of drug resistant 
TB, and is recommended by the World Health Organization for MDR-TB treatment [16]. In addition, 
moxifloxacin may be effective against a significant proportion of isolates phenotypically resistant to ofloxacin 
or ciprofloxacin [17,18] and is potentially less likely to promote fluoroquinolone resistance compared to the 
older fluoroquinolones [19-21]. 
Despite these benefits, moxifloxacin use is almost entirely restricted to resource-rich settings – its prohibitive 
cost has forced many to recommend the use of levofloxacin, the S-isomeric form of ofloxacin, for MDR-TB 
treatment in resource-limited settings despite these countries bearing the greatest disease burden. While 
levofloxacin is likely to be an improvement over ofloxacin [22,23], its molecular similarity suggests a 
high degree of cross-resistance with ofloxacin [24]. Preliminary data from Latvia suggests good treatment 
outcomes are achievable for XDR-TB patients treated with a moxifloxacin-containing regimen [25]. 
Therefore, moxifloxacin most likely offers the best chance of cure for patients with MDR-TB and those with 
undetected fluoroquinolone resistance and XDR-TB. 
Currently, MSF are working internationally to improve access to moxifloxacin for DR-TB patients. The use 
of moxifloxacin in Khayelitsha, while improving outcomes for individual patients, also serves to provide 
evidence for global advocacy efforts regarding moxifloxacin access and affordability. 18
groups have been set up in each of the Khayelitsha 
clinics to provide a forum for discussion and peer 
support for patients throughout the duration of 
their DR-TB treatment. The peer educators are 
members of the support groups who are identified 
by the counsellors as being particularly adherent 
to treatment, with a good understanding of their 
disease and able to support other patients. They 
assist the counsellors on a daily basis to run each 
of the support groups in the different clinics; 
this position is replaced by different support 
group members every three months. The DR-TB 
counsellors are also available throughout treatment 
for ongoing advice and counselling, particularly 
for those patients with problems adhering to 
treatment. The counsellors also regularly visit and 
provide support to patients during admission in 
the TB hospitals and in the sub-acute in-patient 
facility, Lizo Nobanda, which is located within the 
community in Khayelitsha.  
Patients with DR-TB are severely limited in their 
capacity to work, both directly due to the impact 
of their illness and sometimes due to the risk of 
further disease transmission. While all DR-TB 
patients in South Africa qualify for a State Disability 
Grant, many patients have trouble accessing it for 
a variety of reasons, and receipt of the grant often 
takes at least 4 months from the time treatment 
is initiated. These first months of treatment are 
often the most difficult, when patients are ill and 
receiving daily injections as part of their regimen. A 
dedicated social assistant is available in Khayelitsha 
to assist patients in accessing grants, in addition 
to referring patients to other support services, such 
as those available for substance abuse and hearing 
impairment. 
In Khayelitsha, patients attend clinics daily to 
receive treatment under direct observation (DOT) 
throughout the full regimen. During the intensive 
phase of treatment, the clinic visit enables patients 
to receive the injection and also allows clinic 
staff to assess patients’ clinical status, monitor 
adherence and detect potential side effects early. 
A standardised monitoring chart was introduced 
to guide doctors and nurses in managing DR-TB 
patients, and summarises the parameters necessary 
to monitor adverse events and guide treatment 
duration. This chart has been distributed for use in 
clinics in other sub-districts outside of Khayelitsha. 
Beyond the intensive phase, when patients are 
stable, culture-converted (i.e. no longer sputum 
culture positive) and only receiving oral drugs, 
daily attendance at the clinic is demanding and 
perhaps unnecessary to ensure adherence. For 
these reasons, a network of community treatment 
supporters for patients on continuation phase 
was established in one clinic in November 2009 
to assess the feasibility of further roll out across 
Khayelitsha. Each patient is allocated a treatment 
supporter living nearby who goes to see the patient 
in their own house every day to watch them taking 
their tablets. The treatment supporter reports 
back to one of the counsellors each month with a 
record of the patient’s adherence and any problems 
encountered. Although only a small number of 
patients have been enrolled into this pilot project, 
all of them have been adherent and have not 
defaulted thus far throughout their 12 – 18 month 
continuation phase of treatment. It is hoped that 
this initiative may be expanded to other clinics in 
2011.  
In order to monitor patients’ attendance at clinics, a 
‘tick sheet’ was introduced whereby the TB nurses 
tick next to a patient’s name each day when they 
administer the patient’s injection and observe the 
patients swallowing their pills. These ‘tick sheets’ 
are reviewed weekly by the TB staff, who then 
inform the counsellors if a patient is starting to 
default treatment. The counsellors trace defaulters 
through phone calls or home visits to identify the 
reason for default. Although intensive defaulter 
tracing was attempted throughout 2009, its limited 
success suggests that resources invested in this 
activity may be better utilised in providing stronger 
support at the time that patients are diagnosed with 19
DR-TB, and during the initial phase of treatment. 
Less intensified efforts are still being made to 
contact patients if they start to default treatment in 
order to identify those patients who might benefit 
from further assistance.
Contact Screening
Close contacts of DR-TB cases (i.e. those living 
in the same household) have a higher risk of 
developing DR-TB than do those in the general 
community [26]. Contact screening is therefore an 
important method for improving case detection and 
to diagnose infectious cases within households, 
thus reducing the risk of future transmission. 
Enhanced contact screening was implemented in 
Khayelitsha from late 2008 through identification 
and recording of household contacts of DR-TB 
patients both at the time of diagnosis in the clinic 
and at the subsequent home visit. Symptomatic 
contacts and all children less than 5 years or who 
are HIV-positive are given a letter stating their 
contact with a confirmed DR-TB patient and are 
advised to attend their local clinic for screening. 
In 2009, 144 of those diagnosed with DR-TB 
had their close contacts screened. In total 574 
individuals were screened, either by asking about 
symptoms or through bacteriologic testing of 
sputum. Of available results (n = 554), children 
aged 5 years or less made up 84 of the contacts, 
while 470 contacts were aged above 5 years. 
Significant numbers of active TB cases were 
diagnosed among these contacts (Figure 6). 
As the diagnosis of any TB in children is difficult 
and there is limited evidence regarding prophylaxis 
and treatment of children with DR-TB, a specialist 
paediatrician has conducted a monthly outreach 
clinic in Khayelitsha since November 2008 to 
assist local medical officers in managing children 
who are exposed to DR-TB. Overall, screening of 
close contacts yields a considerable number of DR-
TB cases, particularly among children aged less 
than 5 years old. It is, however, important to note 
that while efforts are made to screen all paediatric 
contacts, the figures quoted in figure 6 are amongst 
children who attend the specialist clinic. This 
selected sample are likely to be at higher risk of 
TB and so are not necessarily representative of all 
paediatric contacts of DR-TB patients. Additionally, 
the majority of DR-TB diagnosed in very young 
children is presumed to be DR-TB based on the 
drug resistance profile of the index case and an 
assessment of the exposure between the index 
case and the child. Efforts are currently underway 
to improve diagnosis through conducting sputum 
induction in Khayelitsha clinics.
Most index cases will have been infectious for some 
time prior to diagnosis and treatment initiation. 
Therefore, the majority of transmission to household 
contacts undoubtedly takes place prior to diagnosis 
of DR-TB. It is important to note that drug-sensitive 
(DS) TB was diagnosed more often than DR-TB 
among older close contacts of DR-TB index cases. 
Therefore it cannot be assumed that all close 
contacts developing active TB will have DR-TB. 
A: Contacts screened, aged < 5 (N=84)   B: Contacts screened, aged > 5 years (N=470)
Figure 6: TB diagnosed among contacts of DR-TB index cases diagnosed in 2009
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Improving Treatment Outcomes and 
Reducing Mortality
Treatment for DR-TB requires a minimum of 18 
– 24 months and often even longer. As a result, 
analysis of treatment outcomes can only be 
conducted 2 years after patients initiate treatment. 
Given that the Khayelitsha programme was only 
initiated in late 2007, with staged implementation, 
its impact on treatment outcomes for patients 
starting treatment in 2008 or later cannot yet 
be definitively determined. However, there are 
some interim outcomes that have been assessed, 
particularly the impact of the programme on 
reducing mortality and improving survival. 
Treatment outcomes are determined based on the 
WHO recommended definitions [27]. However, 
these definitions were primarily developed based on 
data from the treatment of DR-TB patients without 
HIV co-infection. Given the high and often rapid 
mortality among HIV-positive patients, the definition 
of treatment failure, whereby a patient must remain 
culture positive for at least one year, may not be 
a true reflection of patients in whom treatment is 
failing. Patients often die or default treatment before 
this time.
Although it is still too early to assess improvement 
in treatment success, the absolute number of 
patients accessing DR-TB treatment and being 
given a chance of cure is increasing each year 
(table 4). The proportion of patients defaulting 
treatment remains very high. One of the reasons 
for this is that more people start DR-TB treatment, 
among them patients who would previously have 
not started due to refusing to be hospitalised (table 
4). To date, 36% of patients who started treatment 
in 2008 have defaulted, i.e. interrupted treatment 
2007 2008 2009
Started treatment 96 164 211
Treatment success* 30 (31%) 23 8
Still on treatment 3 (3%) 37 114
Died 27 (28%) 34 (21%) 36 (17%)
Default 31 (32%) 59 (36%) 38 (18%)
Treatment failure 2 (2%) 1 1
Transfer 3 (3%) 10 14
Table 4: Interim treatment outcomes for patients initiated on DR-TB treatment by year 
*Treatment success = ‘cure’ or ‘treatment completion’
for at least 2 months. Further investigation of these 
patients revealed that 30% had subsequently 
died, and 23% had been re-registered to start 
treatment again. The outcomes for the remaining 
47% patients are unknown. The median time on 
treatment before default was 6.4 months (range 
0.4 – 18 months). 
Clearly the level of treatment default in Khayelitsha 
remains concerning. Based on a review of 
counselling and clinic records, the most significant 
factors associated with default were: 
stigma associated with DR-TB 
difficulties associated with the lack of a stable  
home and consequent travel back and forth 
from the Eastern Cape
lack of family support 
Other relevant factors included: 
excessive alcohol use by either patients  
or close household members leading to 
household instability
poor rapport with clinic staff 
difficulties with staying in hospital for long  
periods
the need to work and financially support others 
patients starting to feel better and therefore  
discontinuing treatment
This preliminary review suggests that the factors 
associated with DR-TB treatment default in 
Khayelitsha are often related to the difficult social 
and economic circumstances in which patients 21
live. Complex interventions to reduce default rates 
are required to address these issues in a holistic 
manner. 
Mortality among people with DR-TB in Khayelitsha, 
although remaining high, appears to be improving 
over time (figure 7).  Of those diagnosed with DR-
TB in 2008, 62% were still alive 18 months after 
diagnosis (defined as the date that sputum was 
taken in which DR-TB was first identified). This 
means that overall mortality is 38% (including 
patients not started on treatment), which compares 
favourably with reports from elsewhere in South 
Africa. For example, mortality at approximately 1 
year among patients with MDR-TB in KwaZulu 
Natal is reported at 71% [28]. It is important to 
note, however, that active surveillance has not 
yet been done in order to follow up each patient 
and determine whether they are alive or not, so 
mortality may be somewhat higher than this, 
particularly among patients who have defaulted 
treatment. 
Figure 7: 18-month survival of patients diagnosed with DR-TB in Khayelitsha in 2008 
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Preliminary data also suggests that survival among 
patients infected with TB strains having resistance 
to second-line drugs may be poorer (Figure 8).  
Those in whom no second line DST is available 
also appear to have poorer survival; these are often 
patients who die before treatment can be started. 
Although survival among DR-TB cases overall 
appears to be improving, mortality is much poorer 
for the subgroup of patients who are diagnosed with 
XDR-TB at the outset. Of the 31 patients diagnosed 
from 2008 to 2010 with XDR-TB, 17 (55%) are 
known to have died as of January 2011. It was 
hoped that outcomes would be better for these 
patients than for those in whom XDR-TB develops 
at some point during treatment (for whatever 
reason, such as poor adherence or an inadequate 
regimen). Although this has not yet been 
demonstrated, the strengthened initial regimen has 
only been in place since late 2009 and therefore it 
may still be too early to draw any conclusions. 
Supporting Health Staff
In order to empower existing TB/HIV clinic staff 
to manage DR-TB patients at primary care level, 
a three-day DR-TB training course was developed 
to educate health care professionals on important 
aspects of DR-TB management. This course has 
now been taken over by the City of Cape Town 
Department of Health and is run by doctors, nurses 
and counsellors who routinely manage DR-TB 
patients in the clinics.
Doctors responsible for managing DR-TB patients 
in Khayelitsha are supported in a number of 
ways. Since October 2008, all new DR-TB cases 
diagnosed and initiated on treatment in Khayelitsha 
Figure 8: Survival among DR-TB cases diagnosed in 2008 by drug resistance profile
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are presented and discussed at a monthly patient 
review meeting attended by all clinicians and 
supporting staff. This forum also provides an 
opportunity to discuss more complicated cases 
and learn from the  experience and expertise of 
others. Expert opinion from clinicians outside 
Khayelitsha is also sought when necessary, either 
through requesting their attendance at the monthly 
meetings, or by the clinic doctors taking time out 
to attend clinical discussion meetings with senior 
doctors in the specialist TB hospital or elsewhere. 
In a similar way, the monthly specialist outpatient 
clinic for paediatric DR-TB also aims to build local 
capacity to diagnose and manage paediatric DR-TB 
patients through transfer of skills.
Monitoring Hearing Loss Among DR-
TB Patients 
The second-line injectable agents (amikacin, 
kanamycin and capreomycin) are key drugs in 
the treatment of DR-TB, but carry a significant 
risk of side effects. Among these is the risk of 
ototoxicity (hearing loss and dizziness), which can 
be extremely debilitating for individuals and may 
become irreversible if injections are continued. The 
percentage of patients suffering hearing loss with 
use of these drugs is reported to range between 
7% and 33%, although data is scarce, especially 
for HIV-infected individuals being treated for DR-TB 
[29-31]. 
In the initial stages, the injectable agents may only 
affect the higher frequency wavelengths, without 
the patient actually noticing any change in hearing. 
Further damage may be prevented by adjusting 
the dose and/or frequency of the injectable agent, 
before the hearing loss becomes irreversible. In 
order to identify earlier those patients suffering 
ototoxicity and to more accurately define the risk of 
hearing loss with DR-TB treatment, an audiometry 
screening service has been established in a 
centrally located clinic within the community in 
order to improve access for Khayelitsha patients. 
A small, sound-proof booth was built in the clinic, 
with a hearing screening machine which requires 
annual calibration. A lay staff member was trained 
by an audiologist from the University of Cape Town 
(UCT) to conduct this hearing screening and to 
recognise abnormal test results necessitating earlier 
referral back to the doctor. 
Since the clinic audiometry service was set up in 
August 2009, over 700 audiometry screenings 
have been conducted as part of the DR-TB 
programme in Khayelitsha. This includes screening 
of 140 patients at the time of treatment initiation 
(i.e. baseline screening), with monthly follow-up 
screening throughout the injectable phase. Among 
these patients, 42% showed a significant level of 
baseline hearing loss; this hearing loss may be due 
to previous streptomycin treatment, or other non-
TB related factors. As yet there is insufficient data 
to assess the proportion of patients whose hearing 
deteriorates with DR-TB treatment, but it is thought 
to be significant. Quality assurance for this service 
in Khayelitsha is being carried out in collaboration 
with the UCT audiology department and has been 
excellent for the Khayelitsha service to date. 
Inpatient Care 
While the majority of patients can be started 
on second-line treatment through their local 
clinic, there will always be a need for facilities to 
hospitalise certain patients at treatment initiation if 
they are clinically unwell or at some point during 
their treatment (e.g. for a significant adverse event). 
The specialist TB hospitals in Cape Town that 
provide treatment for DR-TB patients are located a 
considerable distance from Khayelitsha and public 24
transport is poor. As a result, patients admitted to 
hospital in these centres often feel isolated from 
their families and community, particularly if they 
are hospitalised for unnecessarily long periods of 
time (i.e. until culture conversion or the end of the 
intensive phase of treatment). 
In response to this situation, a small, 12-bed 
in-patient facility was established within the 
community of Khayelitsha. This facility, the Lizo 
Nobanda TB Care Centre, can admit patients 
who may be suffering side effects of medication, 
or having trouble with adherence. It can also be 
used for short, 2–3 week hospitalisations in order 
to initiate treatment, particularly for HIV-infected 
patients, who additionally need to start antiretroviral 
treatment (ART). The facility was opened in April 
2009 and to date 111 patient admissions have 
been recorded; including 62 in 2010. As the facility 
is staffed and run by nurses, the clinic doctors 
in their respective clinics remain responsible for 
the care of any of their patients admitted to Lizo 
Nobanda, and are required to review them at 
Effective Utilisation of Hospitalisation for DR-TB 
Treatment
The Lizo Nobanda facility is an example of how hospitalisation can be used within a DR-TB 
programme. While a separate stand-alone facility for DR-TB is not always necessary, there are some 
key requirements for hospitalisation suggested by the experience in Khayelitsha:
Capacity to hospitalise clinically unwell patients to start treatment without delay 
Access to appropriate medical care (nurse-led with weekly doctor visits), and good referral  
system to higher level health services when necessary
Effective infection control measures to protect both staff and other patients from infection 
Proximity to the community in which patients reside, to allow ongoing family and community  
support
Provision of counselling and support with access to social services for admitted patients 
Capacity for appropriate supported end-of-life care 
These requirements could be fulfilled through use of district hospitals, or more effective utilisation of 
existing specialist TB hospitals.
Figure 9: Reason for patient admission to Lizo Nobanda TB Care Centre (Khayelitsha) in 2010
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least once a week. The most common reasons for 
admission in 2010 were:  
The most common reasons for admission in 2010 
were: short-term stay for treatment initiation 
(61%), management of co-morbidities such as 
diabetes and other HIV-related conditions (23%) 
and medication-related side effects during DR-TB 
treatment (8%); see figure 9.
The remaining patients were admitted for a variety 
of reasons including infection control issues at 
home, socio-economic problems, adherence 
support or palliative care. The median length of stay 
for those patients admitted for treatment initiation 
was 23 days, 26 days for management of co-
morbidities, and 30 days for management of side 
effects of DR-TB medication.
Reducing DR-TB Transmission and 
Infection Control
The most effective activity in reducing the 
transmission of DR-TB, and indeed tuberculosis 
in general, is to diagnose as many cases as 
possible, as early as possible and to start them 
on appropriate treatment. To this end, all of the 
activities in Khayelitsha related to improving case 
detection and treatment initiation are aimed at 
reducing transmission and curbing the DR-TB 
epidemic. 
Patients initiated on appropriate second-line 
treatment for DR-TB will have reduced 
infectiousness even before culture conversion. This 
results from both the action of the drugs, and from 
improved cough hygiene and other behaviours such 
as improving ventilation in the home, resulting 
from patient education and counselling. Culture 
conversion is defined for initially culture-positive 
cases as the date of the first of two negative 
cultures at least 1 month apart. Culture conversion 
appears to be rapid in Khayelitsha; by 2 months of 
treatment, more than half (56%) of patients have 
converted an initially positive sputum culture to 
negative (figure 10). This is based on an analysis of 
more than 300 culture positive cases who started 
Figure 10: Culture conversion by month of treatment among 303 culture positive patients starting DR-
TB treatment in 2008 and 2009
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treatment in 2008 and 2009. By 6 months of 
treatment, very few patients remain on treatment 
with positive cultures; the majority of those in 
whom sputum cultures fail to convert to negative 
have died during the first 6 months of treatment, 
most likely indicating treatment failure. 
Specific infection control (IC) measures are also 
initiated in the homes of DR-TB patients, health 
care clinics and in the community. A dedicated 
Infection Control officer has been employed 
in Khayelitsha since 2007 (although with a 
considerable gap through 2010). This position 
works closely with the staff in health care facilities 
to ensure that proper administrative, environmental 
and personal protection measures are in place to 
reduce the spread of infection between patients, 
visitors and staff inside the facilities. In 2007, 
each health care facility in Khayelitsha underwent 
a formal IC assessment; these were repeated in 
2010 and necessary recommendations were made. 
The IC officer worked closely with existing clinic 
administrative and medical staff to re-establish 
the IC committees which had initially been 
identified in 2008 in each of these facilities. She 
provides ongoing support to ensure that each of 
the committees continue to meet regularly, firstly 
to design and implement individualised Infection 
Control Plans and then to ensure supervision 
and monitoring of IC activities and interventions 
within each facility. Structural modifications to 
improve patient flow and ventilation within the 
facilities have been carried out in some clinics and 
recommendations made for others. In addition, 
separate sputum collection booths have been 
constructed to allow privacy for patients while 
reducing the risk of transmission to health care 
staff and others. In the homes of DR-TB cases, 
the emphasis is on counselling and education to 
change behaviour in order to reduce the risk of 
transmission. This includes, for example, cough 
hygiene education to reduce the spray of infectious 
particles when a patient coughs or sneezes. 
Patients and families are also empowered to reduce 
the transmission risk in their homes through 
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improving ventilation and changing sleeping 
arrangements to allow the DR-TB patient to sleep 
separately. The DR-TB counsellors provide this 
education, advice and support, with input from the 
IC officer when needed.
Although efforts are made to reduce the risk of 
transmission in the homes of DR-TB patients 
after they have been diagnosed, the majority of 
transmission to household contacts has most likely 
occurred before this time. However, the emphasis 
on developing an understanding of how TB is 
transmitted, how it is diagnosed and how it is 
treated, is fundamentally important in empowering 
household members and allowing for rapid 
diagnosis of further household members should 
they develop active TB disease. 
There have also been efforts to reduce the risk 
of TB transmission in the community at large 
in Khayelitsha. Public meeting places, such as 
churches, local drinking establishments (i.e. 
shebeens) and taxi ranks have been targeted. In 
particular, a campaign to raise awareness of the 
risk of TB transmission in crowded taxis was started 
in March 2009, with education sessions for taxi 
drivers and the distribution of stickers for display in 
taxis (see box). Two DR-TB counsellors also attend 
a weekly session at the local radio station where 
they have an hour long slot to discuss any DR-TB 
issues with local people calling in to ask questions. 
Programme Management and Human 
Resources 
The DR-TB programme in Khayelitsha is run in 
collaboration between MSF, the City of Cape Town 
and the Western Cape Province Department of 
Health. The aim is to utilise existing services and 
staff wherever possible, in order to develop a model 
of care that is both cost-effective and feasible for 
expansion elsewhere. 
The programme is overseen by a ‘task team’ 
that meets monthly to discuss issues around 
implementation, assess progress, and deal 
with difficulties as they arise. The task team is 
comprised of key staff in the DR-TB programme 
including health care workers treating DR-TB, 
patient support staff, MSF management staff, 
the Khayelitsha manager of health services for 
the City of Cape Town, representatives from DP 
Marais (DPM) and Brooklyn Chest Hospitals 
(BCH), representatives from the Provincial DR-TB 
review panel, district and provincial policy makers, 
managers and stakeholders, and various other 
experts and visitors from outside of Khayelitsha. 
The monthly task team meeting also serves 
as a forum to give feedback related to ongoing 
operational research projects in Khayelitsha such 
as the study on the feasibility of implementing the 
Xpert MTB/RIF rapid diagnostic test for DR-TB and 
studies on improving natural ventilation for TB 
infection control in clinics. This forum is also used 
to discuss particularly difficult or problematic cases 
which raise important issues; external experts are 
often invited to join these discussions on particular 
issues, such as human rights of DR-TB patients, 
DR-TB in children, diabetes in TB/HIV patients, etc.
The numbers of staff involved in providing each 
of the services listed in table 5 has changed 
considerably throughout the implementation of the 
programme in Khayelitsha as the programme has 
evolved, and very much depends on the DR-TB 
burden. It is therefore possible that if case detection 
increases substantially with the introduction of 
rapid testing of all TB suspects, the numbers of staff 
may also need to increase.28
Service Service Provision
Diagnosis of DR-TB
TB staff in primary care clinics (City of Cape Town and Western Cape 
Province)
Green Point laboratory, National Health Laboratory Service
Medical management
Medical officers and TB nurses working in clinics (City of Cape Town, 
Western Cape Province and MSF)
TB nurses and auxiliary staff working in Lizo Nobanda (MSF)
Medical staff at BCH and DPM (Province)
Counselling
Three dedicated DR-TB counsellors (City of Cape Town, TB/HIV Care and   
MSF)
Two peer educators (MSF)
Social assistance Dedicated Social Assistant (MSF)
Audiometry service Dedicated hearing screener (MSF)
Drug supply
All drugs besides moxifloxacin are supplied by the City of Cape Town and 
Western Cape Province Departments of Health. Moxifloxacin is supplied 
by MSF. Drug management by the City of Cape Town
In-patient services Patients admitted to BCH or DPM (Western Cape province)
Lizo Nobanda TB care centre, Khayelitsha (MSF and City of Cape Town)
Data collection and management Data manager (MSF), facility-based DR-TB registers completed by TB 
staff (City of Cape Town)
Programme supervision Two professional nurses (City of Cape Town and MSF)
Programme management  Medical Officer (MSF)
Manager Health Services Khayelitsha (City of Cape Town)
Infection control Infection control officer (MSF)
Evaluation  and  operational 
research
Epidemiologist and two research assistants (MSF) and collaboration with 
the University of Cape Town and the University of Stellenbosch
Training  Collaboration between MSF and City of Cape Town
Transport of staff to clinics, home 
visits and for patients admitted to 
Lizo Nobanda
Two drivers (MSF)
Table 5: List of services and providers that form the DR-TB programme in Khayelitsha29
subsequently defaulted, continued treatment or 
had treatment withdrawn.  There is currently much 
debate regarding the optimal management of 
patients in situations where continuing treatment 
is unlikely to result in cure. Some patients require 
hospital admission at this point due to their 
deteriorating clinical status; however many patients 
remain stable and ambulant for many months 
following treatment withdrawal and would like to 
remain at home with their families. It is necessary 
to put systems in place to ensure that these patients 
continue to have access to medical care, as well as 
to provide psychosocial support to the patient and 
their families in order to optimise their quality of 
life and to reduce the risk of DR-TB transmission to 
others. 
Failure to monitor patients regularly may lead to 
situations where it is too late to intervene with 
additional drugs. Patients may begin to show 
signs of failing treatment before they reach this 
stage; these patients should be targeted to try 
more options with other available drugs. However, 
access to new drugs and Class 5 drugs (those with 
unproven efficacy for DR-TB) is currently limited for 
these patients. 
Current reporting systems for DR-TB rely on paper 
registers at the facility level, however registration 
of patients on the sub-district electronic database 
remains centralised at the specialist TB centres, 
leading to problems with transfer of data between 
facilities. There is a need to register and report 
on patients at the primary care facility level, 
with integration into the existing national TB/HIV 
reporting system. 
While there have been major successes in 
Khayelitsha over the past 3 years, there are a 
number of challenges remaining. Many of these 
are common to DR-TB treatment internationally. 
Over the last decade an estimated 1.5 million 
people have died globally from DR-TB, and barely 
0.5% of the 5 million who developed the disease 
had access to appropriate treatment [32]. There 
is therefore an urgent need to scale up DR-TB 
treatment globally if we are to mitigate the impact of 
this epidemic. Addressing these challenges requires 
continued funding, resources, and especially 
political commitment.
Fundamental to improving access to treatment is 
increasing access to diagnosis. Drug susceptibility 
testing is not currently available for all TB suspects, 
thereby limiting the capacity to increase case 
detection given that more than 50% of cases will 
be ‘new’ and not considered ‘high risk’. 
The reasons for treatment default are numerous and 
complex, and cannot be addressed by counselling 
alone. Patients have complex socioeconomic 
situations and require good psychosocial support to 
address these issues in a holistic manner. Shorter 
treatment regimens and the use of drugs with 
fewer side effects would considerably aid patients’ 
adherence to treatment.  
There is a small proportion of patients whose 
sputum remains culture positive despite a 
prolonged course of treatment with second-line 
DR-TB drugs. In 2008, 172 patients were started 
on DR-TB treatment, and of these, 17 (10%) were 
considered to have failed treatment; just under 
half of these patients died. The remaining patients 
 A TREATMENT FAILURE PATIENT MANAGED IN KHAYELITSHA
Neliswa, a 49-year-old patient, was considered to have failed DR-TB treatment after a long process including a 
number of courses of second line TB drugs. Despite good adherence and a strong personal conviction to finish 
treatment, her sputum remain culture positive. The decision was made to withdraw treatment, and the patient 
was informed that she would unlikely to ever be cured of DR-TB. She survived for a year after treatment was 
withdrawn, and eventually moved out of her home due to her fear of infecting her family members. She moved into 
the sub-acute inpatient facility in the community (Lizo Nobanda) where she required very minimal nursing care 
right until the last few weeks of life, at which point she also received palliative input from local hospice nurses. She 
died peacefully at home while out on a ‘weekend pass’. 
Challenges30
Preliminary results suggest that the Khayelitsha DR-TB model of care is improving case detection, 
decreasing time to treatment initiation, and through a more patient-centred approach, improving patient 
retention and clinical outcomes. A large number of individuals and organisations have contributed to this 
preliminary success – without their motivation and commitment, such success would not be possible.
The process of learning what works and what doesn’t work is ongoing in the Khayelitsha DR-TB 
programme. It is hoped that lessons learned in Khayelitsha will inform policy and practice not just in South 
Africa but also in other settings internationally. 
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